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Abstract
Background: Genome-wide association studies (GWAS) have identified new candidate genes for the occurrence of
acute coronary syndrome (ACS), but possible effects of such genes on survival following ACS have yet to be
investigated.
Methods: We examined 95 polymorphisms in 69 distinct gene regions identified in a GWAS for premature
myocardial infarction for their association with post-ACS mortality among 811 whites recruited from university-
affiliated hospitals in Kansas City, Missouri. We then sought replication of a positive genetic association in a large,
racially diverse cohort of myocardial infarction patients (N = 2284) using Kaplan-Meier survival analyses and Cox
regression to adjust for relevant covariates. Finally, we investigated the apparent association further in 6086
additional coronary artery disease patients.
Results: After Cox adjustment for other ACS risk factors, of 95 SNPs tested in 811 whites only the association with
the rs6922269 in MTHFD1L was statistically significant, with a 2.6-fold mortality hazard (P = 0.007). The recessive A/A
genotype was of borderline significance in an age- and race-adjusted analysis of the entire combined cohort (N =
3095; P = 0.052), but this finding was not confirmed in independent cohorts (N = 6086).
Conclusions: We found no support for the hypothesis that the GWAS-identified variants in this study substantially
alter the probability of post-ACS survival. Large-scale, collaborative, genome-wide studies may be required in order
to detect genetic variants that are robustly associated with survival in patients with coronary artery disease.
Background
Genome-wide association studies (GWAS) have identi-
fied robust genetic associations in a variety of common
diseases [1], including myocardial infarction (MI) [2-6].
The GWAS approach, with its emphasis on large sample
sizes and inclusion of hundreds of thousands of genetic
markers, has produced a degree of reproducibility that
was generally lacking in earlier candidate gene studies of
MI [7]. However, nine GWAS-identified genetic suscept-
ibility markers, all meeting criteria for genome-wide sta-
tistical significance, collectively account for only 3% of
the estimated heritability of early-onset myocardial
infarction (MI), raising questions about the clinical uti-
lity of such markers for predicting MI [1].
In contrast to the identification of risk markers for
incident disease, risk-stratifying patients with established
disease, including those who have suffered an MI, is a
cornerstone of modern cardiovascular care. Yet associa-
tion studies of GWAS-generated candidate genes with
prognosis following acute coronary syndromes (ACS),
including unstable angina, non-ST elevation myocardial
infarction (NSTEMI), and ST-elevation myocardial
infarction (STEMI), require resource-intensive longitudi-
nal designs and have rarely been performed. Although
the post-ACS period is considered high risk, there is
substantial heterogeneity in patient outcomes, and
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risk, guiding treatment, and understanding the mechan-
isms of recurrent events and mortality. In contrast to
genetic screening for incident MI, which requires
screening large populations of patients without recog-
nized disease, prognostically important genetic variations
after an ACS could accelerate translation to clinical
practice by focusing upon a narrower cohort of patients
at high risk. Moreover, the identification of genetic
pathways leading to a poor prognosis following ACS
may identify new pathways of disease progression that
could become novel targets for the chemoprevention of
recurrent ACS.
GWAS-identified risk factors for incident MI pose an
important opportunity to identify genetic markers of
prognosis in an ACS population, given the clinical logic
that a validated risk factor for MI occurrence may also
lead to more rapid disease progression after an initial
event. To test this possibility, we selected as a pool of
candidate prognostic markers the 95 most statistically
significant of approximately 2.5 million genetic variants
tested in a GWAS of premature MI occurrence (Myo-
cardial Infarction Genetics Consortium) [5]. We specifi-
cally tested the hypothesis that these risk markers for
MI would be associated with all-cause mortality within
3 years following ACS.
Methods
Identification of Candidate Genes
We tested 95 SNPs in 63 individual genes, and an addi-
tional 6 distinct gene regions containing more than one
genetic locus. The 95 candidate SNPs were ranked the
most statistically significant (P <1×1 0
-5)o fa l l~ 2 . 5
million SNPs that were included on, or imputed from,
the Affymetrix 6.0 microarray and brought forward into
replication stage 3 of the Myocardial Infarction Genetics
Consortium Study [5].
Study Population and Genotyping
Our study design called for testing genetic markers for
prognostic association with 3-year mortality in an ACS
cohort, and attempting replication of significant associa-
tions in additional cohorts of MI and/or coronary artery
disease (CAD) patients. The discovery cohort was com-
prised of 811 self-reported white patients of European
ancestry with ACS who were identified from a consecu-
tive series of patients presenting to two Kansas City,
MO hospitals (Mid-America Heart Institute and Tru-
man Medical Center), from March 2001 through June
2003. Standard definitions were used to diagnose ACS
patients with either myocardial infarction or unstable
angina [8,9]. Individuals were monitored for incident
deaths from any cause, as determined by periodic
queries of the Social Security Administration Death
Master File [10]. Follow-up was planned for a minimum
of 3-years.
The Translational Research Investigating Underlying
disparities in acute Myocardial infarction Patients’
Health status study (TRIUMPH) served as the replica-
tion cohort, as described in a recent publication [11].
This study recruited several sites that were enriched for
African-American patients with MI and was specifically
designed to address racial disparities in outcomes,
including genetic variations between races. Patients were
adults > 18 years of age with elevated cardiac biomar-
kers (troponin or creatine kinase-MB fraction) as well as
other clinical evidence of MI (ECG ST-segment changes
or prolonged ischemia signs/symptoms). Collected data
included baseline chart abstractions for demographic
and medical history, followed by study coordinators
contacting patients for follow-up interviews at 1, 6, and
12 months after MI. Long-term mortality was assessed
by periodic queries of the Social Security Administration
Death Master File [10].
Additional validation cohorts for survival analysis
involving one SNP, rs6922269 in the MTHFD1L gene,
were provided by Cleveland Clinic GeneBank (coronary
artery disease including acute myocardial infarction)
[12,13], Emory Cardiology Biobank (cardiac catheteriza-
tion patients) [14], and the Ludwigshafen Risk and Car-
diovascular Health (LURIC) study (patients hospitalized
for coronary angiography) [15]. Clinical details of the
cohorts are described in Appendix A.
Genotyping of the 95 SNPs was performed at the
Broad Institute at MIT using the iPLEX MassARRAY
platform (Sequenom) on extracted leukocyte DNA (TRI-
UMPH) or whole genome amplified DNA (Mid-America
Heart cohort) [16,17]. More extensive details of the
cases, DNA extraction methods, and genotyping proce-
dures have been recently described [5,7,18]. Flanking
DNA sequence and other identifiers for each genetic
variant are available upon request from the authors.
Statistical Analysis
Genotype distributions weree x a m i n e df o rs i g n i f i c a n t
deviations (P < 0.05) from Hardy-Weinberg equilibrium
(HWE). Chi-square testing was used to screen for possi-
ble HWE violations, which were further investigated for
statistically significant departure from HWE expecta-
tions by Monte Carlo testing involving 10, 000 random
reshufflings of alleles [19].
Initially, Kaplan-Meier survival analysis was performed
for each variant using SPSS 17.0 (Chicago, IL). The
equality of survival curves was tested by the log-rank
test pooled over all genotypic strata (one degree of free-
dom). If the log-rank P value was < 0.05, then pairwise
log-rank tests were performed to explore which geno-
type or genotypes were most likely to confer mortality
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positive associations for age, sex, hypertension, ACS
type, prior myocardial infarction, prior revascularization,
congestive heart failure, diabetes, renal failure, marital
status, educational level, menopause, and smoking and
alcohol use prior to the ACS. We tested proportional-
hazards assumption for each covariate using Shoenfeld
residuals. We report raw P values and considered the
conservative Bonferroni correction (0.05/95 = 0.0005) to
represent the study-wide statistical significance thresh-
old [20], but in addition to considering chance, we also
considered canonical epidemiological principles of cau-
sation, including magnitude of effect, allelic dose-
response, and adjustment for confounding.
Our sample had 93% power to detect an association,
by the log rank test (P < 0.05), for a hazard ratio of 2.5
or higher, given a frequent genotype (0.5), and 80%
power to detect a hazard ratio of 3.3 or higher, given an
infrequent genotype (0.1) [21]. Given that genetic var-
iants conferring more modest effects may not reach the
conventional statistical significance level of P <0 . 0 5 ,w e
sought to explore the possibility that null results might
be related to lack of power (type II error), by examining
the characteristics of the overall P value distribution by
visualizing a Q-Q plot (quantile-quantile) using SPSS
17.0 (Chicago, IL).
Results
The clinical characteristics of the 811 cases are
described in Table 1. The population of ACS cases
included 308 STEMI (38%), 284 NSTEMI (35%), and
2 1 9u n s t a b l ea n g i n ap a t i e n t s( 2 7 % ) .Af a m i l yh i s t o r yo f
coronary artery disease or myocardial infarction among
first-degree relatives was found in over half of cases
(52%). In addition, cardiac risk factor profiles were typi-
cal of a population with ACS, with over one half of
patients having hypercholesterolemia and hypertension,
a third with history of smoking, and over one fifth with
diagnosed diabetes. Previous revascularization had been
performed in over a third of the cases.
There were 90 deaths in the cohort, which was fol-
lowed for a mean of 39.1 months, with maximum fol-
low-up time of 60 months. Risk factor data were
missing for 2 individuals. There were marked differences
in overall cardiac risk factor profiles, as expected, with
deceased patients having relatively advanced age, as well
as more extensive cardiovascular co-morbidity, including
congestive heart failure (Table 2).
A total of 95 variants in 69 distinct genes or gene
regions were genotyped. The average genotype call rate
for these variants was 99.3%. Two assays failed (FTO
rs9941349, CETP rs6499863). Eight variants violated
HWE at the P < 0.05 level (additional file 1: Table S1).
The genotype distributions, numbers of deaths by gen-
otypic category, and unadjusted P values for all 95
genetic variables are shown in additional file 1: Table
S1, with the P value distributions summarized in the Q-
Q plot shown in Figure 1. Overall, there were 4 positive
associations (P < 0.05). Three of these associations did
not retain statistical significance in a Cox proportional
hazards adjusted model (rs6458545, P = 0.36; rs769449,
P = 0.41; rs7754840, P = 0.13). However, the MTHFD1L
association with mortality hazard remained statistically
significant following adjustment for traditional cardiac
risk factors. Of these covariates, age (HR 1.04/year; P < Table 1 Characteristics of 811 White Subjects with Acute
Coronary Syndrome at Baseline
Characteristic Male ACS
Cases
(N = 550)
Female ACS
Cases
(N = 261)
Mean age in years (SD) 60.7 (12.5) 63.1 (13.2)
Mean body mass index (SD) 29.1 (5.5) 29.9 (6.9)
Family history of CAD/MI (%) 279 (50.7) 135 (51.7)
Prior myocardial infarction (%) 142 (25.8) 74 (28.4)
Prior revascularization (%) 205 (37.3) 83 (31.8)
Congestive heart failure (%) 23 (4.2) 18 (6.9)
Hypertension (%) 305 (55.5) 182 (69.7)
Diabetes Mellitus (%) 116 (21.1) 77 (29.5)
Hypercholesterolemia (%) 314 (57.1) 162 (62.1)
Postmenopausal (%) – 189 (68.6)
College graduate (%) 166 (30.2) 40 (15.3)
Smoking < 30 days ago (%) 183 (33.3) 85 (32.6)
Alcohol frequency > 1/month
(%)
221 (40.2) 38 (14.6)
Continuous variables are shown as mean (SD); categorical variables are
number (%)
Table 2 Clinical Characteristics of Surviving and Deceased
Patients in the Follow-up Cohort
Characteristic Survivors
(N = 721)
Deceased
(N = 90)
Mean age in years (SD)‡ 60.5 (12.5) 69.5 (11.6)
Mean body mass index (SD) 29.4 (6.0) 28.8 (6.6)
Family history of CAD/MI (%) 374 (52.0) 40 (44.4)
Prior myocardial infarction(%)‡ 176 (24.5) 40 (44.4)
Prior revascularization (%)‡ 241 (33.5) 47 (52.2)
Congestive heart failure (%)‡ 28 (3.9) 13 (14.4)
Hypertension (%)* 423 (58.8) 63 (70.0)
Diabetes Mellitus (%)‡ 150 (20.9) 43 (47.8)
Hypercholesterolemia (%) 419 (58.3) 57 (63.3)
College graduate (%) 185 (25.9) 19 (21.6)
Smoking < 30 days ago (%)* 249 (34.7) 18 (20.0)
Alcohol frequency > 1/month (%)‡ 348 (55.8) 19 (24.4)
Continuous variables are shown as mean (SD); categorical variables are
number (%)
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infarction (HR 1.7; P = 0.04), congestive heart failure
(2.0; P = 0.04), and unmarried status (HR 1.3; P =
0.003) had significant associations with mortality when
modeled independent of genotype. The A/A genotype
(versus G/G reference) of the mitochondrial-expressed
MTHFD1L (methylenetetrahydrofolate dehydrogenase
(NADP+ dependent) 1-like) gene variant rs6922269 was
associated with hazard ratio of 2.6 (P = 0.007). The pair-
wise Kaplan-Meier analysis showed significant differ-
ences for the comparison of A/A vs G/G (P = 0.01), and
A/G vs G/G (P =0 . 0 2 ) ,b u tn o tA / Av sA / G( P = 0.35),
implicating the A allele as a risk factor. Of the 12 A/A
individuals who died (50% female), frequent co-morbid-
ities were hypertension (N = 9), current or former
smoking (N = 9), no current alcohol consumption (N =
9), hyperlipidemia (N = 8), family history of coronary
artery disease (N = 8), and type 2 diabetes (N = 7).
However, the frequencies of such co-morbidities were
not significantly different from the 78 other deceased
patients with any other MTHFD1L rs6922269 genotype.
In order to limit multiple comparisons, only the
MTHFD1L rs6922269 variant was brought forward for
additional genotyping in the TRIUMPH cohort. In order
to maximize power, the entire group of patients was
subjected to combined Kaplan-Meier and Cox regres-
sion analysis. Characteristics, by genotype, of the entire
study group appear in Table 3. As expected, mean fol-
low-up time did not significantly differ by genotype. The
A/A genotype of rs6922269 was strongly associated with
all-cause mortality in the entire group (Figure 2; P <
0.0001). However, after adjustment for age, sex, and
race, the hazard ratio for mortality in association with
the A/A genotype was 1.35, with a borderline statisti-
cally significant P value of 0.052. Although sample size
was too limited to document any formal trend towards
increased mortality risk by number of A alleles, a sug-
gestive decrement in risk was observed in Cox-adjusted
hazard ratios, from 1.35 (A/A), to 1.21 (A/G) to 1.0 (G/
G reference), as shown in Table 4. In the TRIUMPH
replication cohort alone (N = 2284), a striking racial
dichotomy was noted, with the lowest survival rate
(81%) observed in African-American A/A homozygotes
(additional file 1, Table S2), compared with 90% or
greater survival in all other genotype categories for
Whites and African-Americans. The difference in survi-
val by genotype was statistically significant in African-
Americans (P = 0.015) but not in Whites (P = 0.284).
Given the equivocal, but nominally statistically signifi-
cant, results in our primary replication cohort, we colla-
borated with independent investigators to determine the
Figure 1 Kaplan-Meier log-rank Q-Q Plot of for 95 Genetic
Variants.
Table 3 Characteristics of patients by MTHFD1L genotype (N = 3095)
Outcome GG
(n = 1366)
AG
(n = 1327)
AA
(n = 402)
P Value
Patient Died 395 (12.8%) 137 (10.0%) 182 (13.7%) 76 (18.9%) < 0.001
Time (Year) 0.120
Mean ± SD 2.8 ± 1.2 2.8 ± 1.1 2.7 ± 1.2 2.8 ± 1.4
Median (IQR*) 2.7 (2.0, 3.6) 2.8 (2.1, 3.7) 2.6 (2.0, 3.6) 2.8 (1.8, 3.6)
Demographics and History
Age 59.3 ± 12.5 59.9 ± 12.2 59.1 ± 12.8 57.9 ± 12.4 0.010
Sex 0.003
Male 2095 (67.7%) 944 (69.1%) 909 (68.5%) 242 (60.2%)
Female 1000 (32.3%) 422 (30.9%) 418 (31.5%) 160 (39.8%)
Race Category < 0.001
White/Caucasian 2315 (74.9%) 1189 (87.3%) 943 (71.1%) 183 (45.6%)
Black/African American 607 (19.7%) 109 (8.0%) 303 (22.9%) 195 (48.6%)
Other 167 (5.4%) 64 (4.7%) 80 (6.0%) 23 (5.7%)
Unknown 6 4 1 1
*IQR: interquartile range
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other cohorts of patients with CAD. Raw survival data
are shown in Table 5. The overall proportion of deaths
in all patients combined, by genotype, was essentially
the same across all studies. Table 3 (additional file 1)
presents the A allele frequency of the rs6922269 SNP of
MTHFD1L, showing high similarity of race-specific allele
frequencies across sites. Each site performed a standar-
dized Cox proportional hazards analysis, stratified by
race (if applicable) and adjusted for age and sex. The A/
A genotype was not associated with mortality in any of
the 3 independent cohorts. In the Emory cohort, among
African-Americans with CAD, the A/A genotype hazard
ratio (compared to G/G reference) was 1.126 (95% CI,
0.458 - 2.770; p = 0.796). Among whites, the HR was
0.684 (95% CI, 0.297 - 1.578; p = 0.684). Similar results
for whites were obtained in the Cleveland Clinic cohort
(A/A = 0.834 (95% CI, 0.402 - 1.728; p = 0.624) as well
as the LURIC cohort (A/A = 0.846 (95% CI, 0.657 -
1.090; p = 0.196), which had the longest follow-up of
any study, with a median follow-up of 10.1 years. The
corresponding median follow-up time in the Emory
cohort was 2.4 years, and for Cleveland Clinc, it was 3
years.
Discussion
We initially found a nominally statistically significant
association between the A/A genotype of MTHFD1L
and mortality in an initial cohort of 811 white patients
with ACS. However, in the primary replication cohort,
as well as three additional replication cohorts of patients
with MI and/or CAD, this association was not con-
firmed, with a total of over 9, 000 patients studied.
Our experience in this study highlights that robust
replication in multiple independent studies is a critical
criterion for judging the validity of genetic associations.
However, assembling the clinical data required to per-
form such replication studies is challenging, given that it
may require not only the ascertainment of many thou-
sands of patients, but also oversampling for minorities
(by race and/or sex), and then tracking outcomes for
many years. Our report of survival data for multiple
high-priority SNPs advances the relatively neglected
field of post-ACS genetic prognosis.
Although chance is the likely explanation for the
apparently statistically significant association that we
initially observed between mortality and rs6922269,
other epidemiological factors should be considered in
judging the cause-effect relationship between a putative
risk factor and an outcome. In particular, prior evidence
that the A allele is a risk factor for myocardial infarction
is equivocal. Two major independent GWAS have
reported the A allele of MTHFD1L to be associated with
early-onset myocardial infarction [5,22]. First, the Well-
come Trust Case Control Consortium (WTCCC)
reported a per-allele risk of 1.23 [1.15-1.33] for the A
allele of rs6922269 and coronary artery disease, with a
genome-wide statistical significance of 2.90 × 10
-8 [22].
Subsequently, the transatlantic Coronary ARtery DIsease
Genome wide Replication and Meta-analysis (CARDIo-
G R A M )c o n s o r t i u mp e r f o r m ed a meta-analysis of 14
GWAS studies (22, 233 cases, 64, 763 controls), and
MTHFD1L A risk allele not among the statistically sig-
nificant genome-wide associations (P =7 . 3 8×1 0 - 5 ;A
frequency 0.28) [23]. The A allele was not associated
with the presence of significant coronary arterial steno-
sis in a series of consecutive patients referred for coron-
ary angiography due to known or suspected stable CAD
[24].
Clearly, even findings that meet accepted genome-
wide criteria for statistical significance in individual stu-
dies should be replicated widely before genetic associa-
tions are accepted as valid and robust. In addition, in
Figure 2 Kaplan-Meier Survival Curve for MTHFD1L rs6922269
(N = 3095).
Table 4 Cox proportional hazards analysis involving all
patients (N = 3095)
Variable Hazard
ratio
95% confidence
interval
Chi-Square
P
Age 1.05 (1.04-1.05) < .0001
Male sex 1.05 (0.85-1.29) 0.66
Black race 2.56 (2.05-3.20) < .0001
MTHFD1L A/
A*
1.35 (1.00-1.82) 0.05
MTHFD1L A/
G*
1.21 (0.97-1.52) 0.09
*Reference genotype G/G
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culations for prognostic studies may need to posit effect
sizes at least as small as those that have emerged from
GWAS studies of the occurrence of CAD, which are typi-
cally substantially less than 1.4. The challenge of muster-
ing sufficient power is further amplified in prognosis
studies by the fact that only a small proportion of
patients will experience mortality within several years of
follow-up. Therefore, sample size requirements for prog-
nostic studies are expected to be at least as large as those
for case-control studies. While it is beyond the scope of
the present study to prescribe detailed sample size
recommendations for future studies of prognosis in
patients with common cardiovascular diseases, we would
note that the CARDIoGRAM consortium included 22,
233 patients with CAD, with an approximate 3:1 control-
to-case ratio. In addition to requiring large sample sizes,
considerations for oversampling clinically relevant sub-
groups, outcome adjudication, and genotyping scope and
methods are all emerging challenges to field of cardiovas-
cular genetics as it seeks to leverage genetic risk factors
to better risk-stratify outcomes in AMI suvivors. Addi-
tional limitations to this study include the heterogeneity
of the present study, with respect to rs6922269 and our
inability to discern whether or not there could be an
effect in particular subgroups of patients, given the over-
all absence of a significant association.
Conclusions
We found no convincing support for the hypothesis that
SNPs identified from GWAS studies of cardiac risk are
associated with all-cause mortality following ACS, sug-
gesting that independent GWAS studies of cohorts of
many thousands of ACS patients may be required in
order to identify prognostic factors in biological path-
ways promoting post-ACS mortality.
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